Providing Scholarships, Class Reunion Assistance, and More...

Celleration initiates enrollment in MIST Therapy study for VLU Celleration.

The design of IN-Stability VLU was predicated on insight from the world’s leading wound treatment clinicians and researchers, commented Mark Wagner, Celleration‘s president and CEO. .. Celleration initiates enrollment in MIST Therapy study for VLU Celleration, Inc., a privately-held medical device business focused on commercializing and developing therapeutic ultrasound healing technologies, announced the first patient enrollment in IN-Stability VLU . Related StoriesCombination of ultrasound and mammography detects extra cancers in Japanese womenMesenchymal stem cell exosomes present hope in healing persistent woundsClinical trial initiated to determine feasibility, safety of focused ultrasound to treat depressionIN-Stability VLU is a potential, randomized, controlled, multi-center study of MIST Therapy in persistent lower extremity venous ulcers .The study is published in the Journal of the American College of Cardiology, January 16th 2006.. Altheos to invest in development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing Altheos, Inc., a kept early-stage biopharmaceutical organization privately, announced today that it provides completed a $20 million Series A financing led by Bay City Capital. The license also includes a series of highly active compounds specifically for localized treatment for glaucoma.